keyword
MENU ▼
Read by QxMD icon Read
search

Cardiovascular risk HIV

keyword
https://www.readbyqxmd.com/read/29045253/gut-microbial-diversity-in-hiv-infection-post-combined-antiretroviral-therapy-a-key-target-for-prevention-of-cardiovascular-disease
#1
Mohamed El-Far, Cécile L Tremblay
PURPOSE OF REVIEW: Although the HIV-infected population is living longer and getting older under current treatment regimens, significant challenges arise for health management as the infection is associated with various premature aging phenotypes, particularly increased incidence of cardiovascular diseases (CVDs). Here we review the current understanding of HIV-related gut dysbiosis in association with CVD and advances in clinical trials aiming to restore gut microbial diversity. RECENT FINDING: Identification of a unique signature for gut dysbiosis in HIV infection between different cohorts remains challenging...
October 17, 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/29044011/antiretroviral-therapy-and-arterial-elasticity-in-hiv-infected-patients
#2
Mariana A Kundro, Guillermo A Viloria, Javier J Toibaro, Marcelo H Losso
Cardiovascular risk is increased in HIV-infected patients and has become a leading cause of morbi-mortality in this population. The purpose of this study is to compare HIV-infected patients on antiretroviral therapy (ART) and ART-naïve HIV-infected patients regarding arterial elasticity. From September 2010 to September 2015, 105 HIV-infected subjects were enrolled, 41 ART-naïve and 64 on ART with stable viral suppression. Elasticity of large and small arteries (LAE and SAE) was assessed by analysis of radial pulse waveforms using a calibrated device...
2017: Medicina
https://www.readbyqxmd.com/read/29038899/the-use-of-primary-prevention-statin-therapy-in-those-predisposed-to-atherosclerosis
#3
REVIEW
Michael Garshick, James A Underberg
PURPOSE OF REVIEW: Many guidelines exist for the use of statins in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). Few have focused on disease specific states that predispose to ASCVD. This review is intended to focus on the recommendations and evidence in inflammatory diseases that predispose to an increased risk of ASCVD beyond what conventional cardiac risk scores would predict. RECENT FINDINGS: Certain autoimmune inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematous (SLE), and psoriasis/psoriatic arthritis have all been shown to increase the risk of ASCVD...
October 17, 2017: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/29038665/c-reactive-protein-as-an-independent-cardiovascular-risk-predictor-in-hiv-patients-a-focused-review-of-published-studies
#4
REVIEW
Tarvinder S Gilotra, Stephen A Geraci
Patients infected with the human immunodeficiency virus (HIV+) are living longer and at heightened risk for developing cardiovascular events (CVEs). Commonly used prediction tools appear to misrepresent their CVE risk to varying degrees and in varying directions. Inclusion of markers of cellular infection, chronic immune activation and/or systemic inflammation into risk models might provide better predictive accuracy. Observational studies assessing the relationship of high-sensitivity C-reactive protein (hs-CRP) to CVE in HIV+ patients have reported inconsistent findings...
November 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/29035945/the-functional-consequences-of-the-microbiome-in-hiv-insights-from-metabolomic-studies
#5
Sergio Serrano-Villar, Santiago Moreno, Manuel Ferrer
PURPOSE OF REVIEW: It is critical to gain insight into the metabolic pathways by which the microbiota might influence HIV immunopathogenesis to exploit host-microbiota interactions. The aim of this review is to sketch a very broad picture of recent advances in our knowledge of how HIV might affect the microbiota, with a focus on specific gene products, particularly, metabolites produced by the microbiota that may affect HIV immunopathogenesis. RECENT FINDINGS: First, we describe the different approaches used to explore imbalances in effector microbial products during HIV infection...
October 14, 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/29032396/assessing-adherence-to-antihypertensive-therapy-in-primary-health-care-in-namibia-findings-and-implications
#6
M M Nashilongo, B Singu, F Kalemeera, M Mubita, E Naikaku, A Baker, A Ferrario, B Godman, L Achieng, D Kibuule
INTRODUCTION: Namibia has the highest burden and incidence of hypertension in sub-Sahara Africa. Though non-adherence to antihypertensive therapy is an important cardiovascular risk factor, little is known about potential ways to improve adherence in Namibia following universal access. The objective of this study is to validate the Hill-Bone compliance scale and determine the level and predictors of adherence to antihypertensive treatment in primary health care settings in sub-urban townships of Windhoek, Namibia...
October 14, 2017: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29029103/cardiovascular-disease-prevention-policy-in-hiv-recommendations-from-a-modelling-study
#7
Mikaela Smit, Rosan A van Zoest, Brooke E Nichols, Ilonca Vaartjes, Colette Smit, Marc van der Valk, Ard van Sighem, Ferdinand W Wit, Timothy B Hallett, Peter Reiss
Background: Cardiovascular disease (CVD) is expected to contribute a large non-communicable disease burden amongst HIV-positive people. We quantify the impact of prevention interventions on annual CVD burden and costs amongst HIV-positive people in The Netherlands. Methods: We constructed an individual-based model of CVD in HIV-positive people using national ATHENA cohort data on 8,791 patients on combination antiretroviral therapy (cART). The model follows patients as they age, develop CVD (by incorporating a CVD risk equation) and start cardiovascular medication...
October 6, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29025833/prevalence-and-incidence-of-hypertension-in-the-global-hiv-infected-population-a-systematic-review-and-meta-analysis-protocol
#8
Jean Joel Bigna, Aurel T Tankeu, Arnaud D Kaze, Jean Jacques Noubiap, Jobert Richie Nansseu
INTRODUCTION: Hypertension, representing one of the most frequent cardiovascular risk factors, is thought to increase in individuals living with HIV as well as in general population, but summarised global data on the topic are scarce. We conduct this systematic review and meta-analysis to assess the prevalence/incidence of hypertension in the global HIV-infected population. METHODS AND ANALYSIS: This review will include observational studies conducted among HIV-infected people, which reported prevalence/incidence of hypertension or enough data for its appraisal...
October 12, 2017: BMJ Open
https://www.readbyqxmd.com/read/29024496/higher-levels-of-cystatin-c-in-hiv-aids-patients-with-metabolic-syndrome
#9
Gordana Dragović, Danica Srdić, Khawla Al Musalhi, Ivan Soldatović, Jovana Kušić, Djordje Jevtović, Devaki Nair
Data about Cystatin-C levels in HIV-infected patients with metabolic syndrome (MetS) are still limited. Therefore, the aim of this study was to evaluate the possible correlations of serum levels of Cystatin-C in HIV/AIDS patients treated with combined antiretroviral therapy (cART) with or without MetS. This cross-sectional study included 89 HIV/AIDS Caucasian patients receiving cART at the HIV/AIDS Centre Belgrade, Serbia, divided into two groups according to the presence of MetS. Cystatin-C and other biochemical parameters were measured using Cytokine-Array-I, Metabolic-Array-I and Metabolic-Array-II, at the Department of Clinical Biochemistry, Royal Free Hospital and University College London, United Kingdom...
October 11, 2017: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29021266/imaging-to-end-points-cardiovascular-disease-risk-assessment-in-hiv
#10
EDITORIAL
Ahmed M Gharib, Colleen Hadigan
No abstract text is available yet for this article.
October 2017: Circulation. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29021257/presence-characteristics-and-prognostic-associations-of-carotid-plaque-among-people-living-with-hiv
#11
Sumbal A Janjua, Pedro V Staziaki, Balint Szilveszter, Richard A P Takx, Thomas Mayrhofer, Orla Hennessy, Hamed A Emami, Jakob Park, Alexander Ivanov, Travis R Hallett, Michael T Lu, Javier M Romero, Steven K Grinspoon, Udo Hoffmann, Markella V Zanni, Tomas G Neilan
BACKGROUND: Data from broad populations have established associations between incidental carotid plaque and vascular events. Among people living with HIV (PLWHIV), the risk of vascular events is increased; however, whether incidental carotid plaque is increased and there is an association between incidental carotid plaque, plaque characteristics, and vascular events among PLWHIV is unclear. METHODS AND RESULTS: Data from the multi-institutional Research Patient Data Registry were used...
October 2017: Circulation. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29020184/risk-of-acute-liver-injury-after-statin-initiation-by-human-immunodeficiency-virus-and-chronic-hepatitis-c-virus-infection-status
#12
Dana D Byrne, Janet P Tate, Kimberly A Forde, Joseph K Lim, Matthew Bidwell Goetz, David Rimland, Maria C Rodriguez-Barradas, Adeel A Butt, Cynthia L Gibert, Sheldon T Brown, Roger Bedimo, Matthew S Freiberg, Amy C Justice, Jay R Kostman, Jason A Roy, Vincent Lo Re
Background: Patients with human immunodeficiency virus (HIV) and/or chronic hepatitis C virus (HCV) infection may be prescribed statins as treatment for metabolic/cardiovascular disease, but it remains unclear if the risk of acute liver injury (ALI) is increased for statin initiators compared to nonusers in groups classified by HIV/HCV status. Methods: We conducted a cohort study to compare rates of ALI in statin initiators vs nonusers among 7686 HIV/HCV-coinfected, 8155 HCV-monoinfected, 17739 HIV-monoinfected, and 36604 uninfected persons in the Veterans Aging Cohort Study (2000-2012)...
August 16, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28994502/pro-protein-subtilisin-kexin-9-pcsk9-inhibition-in-practice-lipid-clinic-experience-in-2-contrasting-uk-centres
#13
Monika Kohli, Kinjal Patel, Zofia MacMahon, Radha Ramachandran, Martin A Crook, Timothy M Reynolds, Anthony S Wierzbicki
BACKGROUND: Prescribing criteria have been suggested for proprotein convertase subtilisin kexin-9 (PCSK-9) inhibitors but few studies exist of their real-world effectiveness. METHODS: This study audited PCSK-9 inhibitor therapy in 105 consecutive patients from two hospital centres-a university hospital (UH; n = 70) and a district general hospital (DGH; n = 35). Baseline characteristics including cardiovascular disease risk factors, NICE qualification criteria, efficacy and side effects were assessed...
October 10, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28994444/biomarkers-of-monitoring-and-functional-reserve-of-physiological-systems-over-time-in-hiv-expert-opinions-for-effective-secondary-prevention
#14
Massimo Andreoni, Chiara Mussi, Rita Bellagamba, Francesco Di Campli, Vincenzo Montinaro, Claudio Babiloni
HIV-positive individuals are more vulnerable to poor health than HIV-negative individuals. This vulnerability is characterized by a higher risk of several common, age-related health problems, even after adjustment for established risk factors. This expert opinion report aims at identifying the optimal biomarkers for monitoring the structural integrity and function of physiological systems at risk across aging in HIV-seropositive subjects. These biomarkers, readily available locally and relatively cost-effective for clinicians in primary and secondary care, should allow early detection of the first preclinical structural and functional changes in renal, brain, cardiovascular, and skeleton systems or apparatus in HIV subjects across aging (Table 8)...
October 10, 2017: New Microbiologica
https://www.readbyqxmd.com/read/28992467/effect-of-statin-on-arginine-metabolites-in-treated-hiv-infection
#15
Sahera Dirajlal-Fargo, Vanessa El Kamari, Abdus Sattar, Khurshid Alam, Nicholas Funderburg, Danielle Labbato, Lisa Pirro, Chris T Longenecker, Wai Hong Wilson, Grace A McComsey
BACKGROUND AND AIMS: Asymmetric dimethylarginine (ADMA) is an inhibitor of nitric oxide and an independent risk factor for cardiovascular disease. We examined the effect of statin on ADMA in HIV + patients on stable ART, and whether such an effect contributes to the favorable changes on carotid intima media thickness. METHODS: This is a secondary analysis of SATURN-HIV, in which HIV + adults on stable ART with HIV-1 RNA< 1000 copies/mL and LDL-cholesterol <130 mg/dL were randomized to 10 mg daily rosuvastatin or placebo...
September 28, 2017: Atherosclerosis
https://www.readbyqxmd.com/read/28991883/inflammation-related-morbidity-and-mortality-among-hiv-positive-adults-how-extensive-is-it
#16
Brian B Hart, Anna D Nordell, Jason F Okulicz, Adrian Palfreeman, Andrzej Horban, Eynat Kedem, Jacqueline Neuhaus, David R Jacobs, Daniel A Duprez, James D Neaton
OBJECTIVE: To determine the rate of grade 4, potentially life-threatening, events not attributable to AIDS, cardiovascular disease (CVD) or non-AIDS cancer among participants on antiretroviral therapy (ART), and to describe associations of these events with interleukin-6 and D-dimer. DESIGN: Cohort study. METHODS: HIV-infected participants on ART (N=3,568) with an HIV RNA level ≤ 500 copies/mL were followed for grade 4, AIDS, CVD, non-AIDS cancer and all-cause mortality events...
October 4, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28984703/pathophysiology-of-ischaemic-heart-disease
#17
Mamatha O Pocock, Lucy Dorrell, Paola Cicconi
PURPOSE OF REVIEW: To summarize recent findings in the pathogenesis of ischemic heart disease (IHD) in people living with HIV (PLWH). RECENT FINDINGS: PLWH have an elevated risk of IHD. Although incidence is declining, this condition still represents a major cause of non-AIDS-related mortality. The cause is likely multifactorial: traditional risk factors play an important role and IHD risk might be reduced with greater emphasis on primary prevention. The contribution of specific antiretroviral agents to IHD risk is changing as antiretroviral coverage increases globally and as safer agents have replaced drugs with well-described metabolic toxicities...
November 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/28984701/hiv-related-cardiovascular-disease-closing-the-gap-in-mortality
#18
Cameron J Holloway, Franck Boccara
: This series of review articles outlines the complex cause of HIV-related cardiovascular diseases (CVDs) particularly the interactions of viral factors, complications of antiviral therapy such as metabolic derangement, and chronic systemic inflammation. These factors, directly stemming from chronic HIV infection, are important in the pathogenesis of HIV-related CVD. Addressing each issue has likely underpinned the improved morbidity and increased life expectancy enjoyed by patients in the modern era of HIV management...
November 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/28975270/lung-cancer-mortality-associated-with-smoking-and-smoking-cessation-among-people-living-with-hiv-in-the-united-states
#19
Krishna P Reddy, Chung Yin Kong, Emily P Hyle, Travis P Baggett, Mingshu Huang, Robert A Parker, A David Paltiel, Elena Losina, Milton C Weinstein, Kenneth A Freedberg, Rochelle P Walensky
Importance: Lung cancer has become a leading cause of death among people living with human immunodeficiency virus (HIV) (PLWH). Over 40% of PLWH in the United States smoke cigarettes; HIV independently increases the risk of lung cancer. Objective: To project cumulative lung cancer mortality by smoking exposure among PLWH in care. Design: Using a validated microsimulation model of HIV, we applied standard demographic data and recent HIV/AIDS epidemiology statistics with specific details on smoking exposure, combining smoking status (current, former, or never) and intensity (heavy, moderate, or light)...
September 18, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28974102/the-effect-of-rosuvastatin-on-vascular-disease-differs-by-smoking-status-in-treated-hiv-infection
#20
Corrilynn Olesky Hileman, Grace A McComsey
BACKGROUND: Smoking is an important contributor to cardiovascular disease (CVD) risk and is highly prevalent in the HIV population. In SATURN-HIV, a 96-week, randomized placebo-controlled trial testing the effect of rosuvastatin on subclinical vascular disease and immune activation in HIV-infected adults, rosuvastatin improved immune activation and arrested common carotid artery intima media thickness (CCA IMT) progression. METHODS: In this exploratory analysis, ANOVA was used to test for effect modification by smoking...
October 3, 2017: AIDS Research and Human Retroviruses
keyword
keyword
60597
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"